Display Options:
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Bacterial DNA-directed RNA polymerase inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: IMMUNE SYSTEM; OTHER
THERAPEUTIC INDICATION: Cholangitis, Sclerosing; Neoplasms; Persian Gulf Syndrome; Alzheimer Disease; Anemia, Sickle Cell; Breast Neoplasms; Diverticulitis; Dyspepsia; HIV Infections; Heart Failure, Systolic; Hepatitis C; Intestinal Pseudo-Obstruction; Rosacea; Vaginosis, Bacterial; Brain Diseases; Clostridium Infections; Colitis, Collagenous; Crohn Disease; Helicobacter Infections; Hepatitis, Alcoholic; Irritable Bowel Syndrome; Liver Cirrhosis; Parkinson Disease; Peritonitis; Rectal Neoplasms; Diarrhea; Hepatic Encephalopathy; Infections
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Voltage-gated calcium channel modulator
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: EMERGENCY MEDICINE; MUSCULOSKELETAL; NEUROLOGY DRUGS & NERVOUS SYSTEM; OTHER
THERAPEUTIC INDICATION: Carcinoma, Squamous Cell; Cough; Oropharyngeal Neoplasms; Pregnancy; Refractive Errors; Alcoholism; Complex Regional Pain Syndromes; Diabetes Mellitus; Dry Eye Syndromes; Irritable Bowel Syndrome; Nausea; Pancreatitis, Chronic; Pruritus; Urinary Bladder, Overactive; Anxiety; Anxiety Disorders; Breast Neoplasms; Chronic Pain; Dementia; Depressive Disorder; Diabetic Neuropathies; Epilepsies, Partial; Epilepsy, Complex Partial; Epilepsy, Tonic-Clonic; Fractures, Bone; Herpes Zoster; Intervertebral Disc Degeneration; Migraine Disorders; Mononeuropathies; Muscle Cramp; Neuralgia, Postherpetic; Neurotic Disorders; Opioid-Related Disorders; Osteoarthritis; Pain; Peripheral Nervous System Diseases; Prostatitis; Radiculopathy; Restless Legs Syndrome; Schizophrenia; Sleep Initiation and Maintenance Disorders; Epilepsy; Fibromyalgia; Neuralgia; Seizures; Spinal Cord Injuries
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Urinary Bladder, Overactive; Polyuria; Urinary Incontinence
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: GABA-A receptor; anion channel positive allosteric modulator
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: NEUROLOGY DRUGS & NERVOUS SYSTEM; OTHER
THERAPEUTIC INDICATION: Marijuana Abuse; Anxiety Disorders; Sleep Apnea, Obstructive; Sleep Initiation and Maintenance Disorders
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: INJECTION; INTRAVENOUS; IV (INFUSION)
STATUS: Approved
THERAPEUTIC AREA: CANCER; OTHER
THERAPEUTIC INDICATION: Chordoma; Endometrial Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Meningeal Carcinomatosis; Primary Myelofibrosis; Thymoma; Thymus Neoplasms; Adenocarcinoma; Biliary Tract Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Large Cell; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Liver Neoplasms; Lymphoma, Large B-Cell, Diffuse; Medulloblastoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neuroendocrine Tumors; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Sarcoma; Thyroid Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms; Adenocarcinoma of Lung; Carcinoma; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Lung Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms; Uterine Cervical Neoplasms; Mesothelioma; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Rickets, Hypophosphatemic; Chronic Kidney Disease-Mineral and Bone Disorder; Hyperparathyroidism, Primary; Memory Disorders; Hyperparathyroidism; Hyperparathyroidism, Secondary; Renal Insufficiency, Chronic; Parathyroid Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Breast Carcinoma In Situ; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Fatty Liver; Lymphoma, Non-Hodgkin; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Severe Acute Respiratory Syndrome; Urinary Bladder Neoplasms; Wounds and Injuries; Aggression; Autistic Disorder; Bipolar Disorder; Breast Neoplasms; Child Development Disorders, Pervasive; Cognitive Dysfunction; Dementia; Depression, Postpartum; Depressive Disorder; Depressive Disorder, Major; Diabetes Mellitus, Type 1; Dysthymic Disorder; Epilepsy; Glomerulonephritis, IGA; Inflammation; Lichen Planus, Oral; Myositis; Oral Ulcer; Periodontitis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Psychotic Disorders; Renal Insufficiency, Chronic; Sarcopenia; Schizophrenia; Stomatitis; Acne Vulgaris; Alzheimer Disease; Atrial Fibrillation; Attention Deficit Disorder with Hyperactivity; Dry Eye Syndromes; HIV Infections; Heart Diseases; Heart Failure; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypertension; Hypertriglyceridemia; Insulin Resistance; Intermittent Claudication; Language Disorders; Lipid Metabolism Disorders; Myocardial Infarction; Myocardial Ischemia; Non-alcoholic Fatty Liver Disease; Peripheral Arterial Disease; Pyelonephritis; Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypothyroidism
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Carcinoma, Squamous Cell; Cheilitis; Uterine Cervical Dysplasia; Acne Vulgaris; Carcinoma, Basal Cell; Keratosis, Actinic; Skin Aging; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Adenocarcinoma of Lung; Astrocytoma; Brain Neoplasms; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colonic Neoplasms; Glioblastoma; Glioma; Hemorrhagic Fever, Ebola; Hepatitis C, Chronic; Kidney Neoplasms; Melanoma; Multiple Myeloma; Oligodendroglioma; Rectal Neoplasms; Adenocarcinoma, Bronchiolo-Alveolar; Adenomatous Polyposis Coli; Biliary Tract Neoplasms; Breast Neoplasms; Diffuse Intrinsic Pontine Glioma; Digestive System Diseases; Ependymoma; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gliosarcoma; Hematologic Neoplasms; Leukemia; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Mesothelioma; Myelodysplastic Syndromes; Nasopharyngeal Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroendocrine Tumors; Ovarian Neoplasms; Polycythemia Vera; Prostatic Neoplasms, Castration-Resistant; Psoriasis; Skin Neoplasms; Thymoma; Urinary Bladder Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Mouth Neoplasms; Neoplasm Metastasis; Pancreatic Neoplasms; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: DNA (cytosine-5)-methyltransferase 1 inhibitor
ROUTE OF ADMINISTRATION: INTRAVENOUS; SUBCUTANEOUS
STATUS: Approved
THERAPEUTIC AREA: HEMATOLOGY; OTHER
THERAPEUTIC INDICATION: Acute Kidney Injury; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Ependymoma; Esophageal Neoplasms; Graft vs Host Disease; Head and Neck Neoplasms; Leukemia, Large Granular Lymphocytic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liposarcoma; Lymphoma, Non-Hodgkin; Myelodysplastic-Myeloproliferative Diseases; Osteosarcoma; Tuberculosis; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Glioma; Hematologic Neoplasms; Hodgkin Disease; Leukemia, Biphenotypic, Acute; Leukemia, Erythroblastic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma, Follicular; Lymphoma, T-Cell, Peripheral; Melanoma; Multiple Myeloma; Myeloproliferative Disorders; Nasopharyngeal Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; beta-Thalassemia; Immunoblastic Lymphadenopathy; Leukemia; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Anemia; Anemia, Refractory, with Excess of Blasts; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Neoplasms; Thrombocytopenia
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Scleroderma, Systemic; Crohn Disease; Dry Eye Syndromes; Leukemia, Myeloid, Acute; Renal Insufficiency, Chronic; Diabetes Mellitus, Type 1; Graft vs Host Disease; Lupus Erythematosus, Systemic; Lupus Nephritis; Nephrotic Syndrome; Uveitis, Intermediate; Immune System Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Estrogen receptor agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Constipation
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: CRL4(CRBN) E3 ubiquitin ligase inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: CANCER; HEMATOLOGY; OTHER
THERAPEUTIC INDICATION: Astrocytoma; Burkitt Lymphoma; Cachexia; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colonic Neoplasms; Diffuse Intrinsic Pontine Glioma; Fallopian Tube Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, B-Cell; Neoplasms; Neuroblastoma; Ovarian Neoplasms; Peritoneal Neoplasms; Rectal Neoplasms; Sarcoma, Kaposi; Urethral Neoplasms; Autistic Disorder; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Complex Regional Pain Syndromes; Crohn Disease; Glioma; Gliosarcoma; Graft vs Host Disease; HIV Infections; Hematologic Diseases; Hematologic Neoplasms; Histiocytosis, Sinus; Hodgkin Disease; Immunoglobulin Light-chain Amyloidosis; Kidney Neoplasms; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Plasma Cell; Leukemia, Prolymphocytic; Leukemia-Lymphoma, Adult T-Cell; Liver Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Myeloproliferative Disorders; POEMS Syndrome; Pancreatic Neoplasms; Polycythemia Vera; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Prostatic Neoplasms; Radiculopathy; Thrombocythemia, Essential; Thyroid Neoplasms; Urinary Bladder Neoplasms; Waldenstrom Macroglobulinemia; Amyloidosis, Familial; Epstein-Barr Virus Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Melanoma; Neoplasm Metastasis; Plasmacytoma; Prostatic Neoplasms, Castration-Resistant; Smoldering Multiple Myeloma; Anemia; Immune System Diseases; Lymphoma, Mantle-Cell; Multiple Myeloma; Myelodysplastic Syndromes
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Iron chelating agent
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Liver Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Anemia; Hemochromatosis; Leukemia, Myeloid, Acute; Mucormycosis; Osteoporosis, Postmenopausal; Anemia, Sickle Cell; Hemosiderosis; Porphyria Cutanea Tarda; Red-Cell Aplasia, Pure; Thalassemia; beta-Thalassemia; Myelodysplastic Syndromes
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Human immunodeficiency virus type 1 protease inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER; PEDIATRICS
THERAPEUTIC INDICATION: HIV Infections; Hemorrhage; Virus Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Bacterial 70S ribosome inhibitor
ROUTE OF ADMINISTRATION: INTRAVENOUS
STATUS: Approved
THERAPEUTIC AREA: DERMATOLOGY
THERAPEUTIC INDICATION: Leukemia, Myeloid, Acute; Liver Cirrhosis, Biliary; Renal Insufficiency, Chronic; Bacteremia; Abdominal Abscess; Diabetic Foot; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Osteomyelitis; Pneumonia, Bacterial; Skin Diseases; Staphylococcal Infections; Bacterial Infections; Infections; Intraabdominal Infections
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Astrocytoma; Brain Neoplasms; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Hypertension, Pulmonary; Kidney Diseases; Leukemia, Promyelocytic, Acute; Liver Diseases; Lymphoma; Multiple Myeloma; Oligodendroglioma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rectal Neoplasms; Sarcoma, Kaposi; Thrombosis; Uterine Cervical Neoplasms; Adenocarcinoma; Adenocarcinoma, Follicular; Adrenal Cortex Neoplasms; Carcinoma, Medullary; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Gliosarcoma; Head and Neck Neoplasms; Hepatopulmonary Syndrome; Hypertension, Portal; Keloid; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Monocytic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lung Neoplasms; Mesothelioma; Myelodysplastic Syndromes; Nasopharyngeal Neoplasms; Neuroblastoma; Neuroendocrine Tumors; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rhabdomyosarcoma; Sarcoma; Small Cell Lung Carcinoma; Stomach Neoplasms; Testicular Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Hepatoblastoma; Kidney Neoplasms; Liver Neoplasms; Melanoma; Thyroid Neoplasms; Carcinoma, Renal Cell; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: GABA-A receptor; anion channel positive allosteric modulator
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: NEUROLOGY DRUGS & NERVOUS SYSTEM; OTHER; PEDIATRICS
THERAPEUTIC INDICATION: Neuralgia; Epilepsy; Dementia; Depressive Disorder; Epilepsia Partialis Continua; Epilepsies, Myoclonic; Low Back Pain; Pain; Schizophrenia; Anxiety; Lennox Gastaut Syndrome; Seizures
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Melatonin receptor agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: NEUROLOGY DRUGS & NERVOUS SYSTEM; OTHER
THERAPEUTIC INDICATION: Marijuana Abuse; Burns; Migraine with Aura; Migraine without Aura; Pulmonary Disease, Chronic Obstructive; Severe Acute Respiratory Syndrome; Sleep Apnea, Obstructive; Substance-Related Disorders; Tobacco Use Disorder; Bipolar Disorder; Depressive Disorder; Sleep Wake Disorders; Sleep Initiation and Maintenance Disorders
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Graft vs Host Disease; Neoplasms; Aspergillosis; Leukemia; Candidemia; Candidiasis; Candidiasis, Invasive; Candidiasis, Oral; Mycoses
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sodium channel alpha subunit blocker
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Osteoarthritis; Carpal Tunnel Syndrome; Myofascial Pain Syndromes; Neuralgia, Postherpetic; Shoulder Impingement Syndrome; Skin Diseases; Tendinopathy; Wounds and Injuries; Cataract; Hemorrhoids; Pain; Pruritus
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Brain Injuries; Heart Failure; Liver Cirrhosis; Hyponatremia; Cardiovascular Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: DNA polymerase/reverse transcriptase inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: IMMUNE SYSTEM; OTHER
THERAPEUTIC INDICATION: Colorectal Neoplasms; Hepatitis C, Chronic; Hepatitis D; Liver Failure; Liver Neoplasms; Stomach Neoplasms; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis B, Chronic; Liver Diseases; Virus Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Cyclooxygenase inhibitor
ROUTE OF ADMINISTRATION: OPHTHALMIC
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Macular Edema; Miosis; Cataract; Eye Diseases; Inflammation
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: DNA inhibitor
ROUTE OF ADMINISTRATION: INTRAVENOUS
STATUS: Approved
THERAPEUTIC AREA: CANCER
THERAPEUTIC INDICATION: Leukemia, Lymphoid; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Leukemia; Leukemia, Biphenotypic, Acute; Lymphoma; Mycosis Fungoides; Sezary Syndrome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia-Lymphoma, Adult T-Cell; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Chronic Pain; Malaria, Falciparum; Malaria
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Chloride channel protein 2 opener
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: GASTROINTESTINAL; OTHER
THERAPEUTIC INDICATION: HIV Infections; Chronic Pain; Constipation; Irritable Bowel Syndrome
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Asthma; Bronchial Spasm; Bronchitis; Bronchitis, Chronic; Emphysema; Pulmonary Disease, Chronic Obstructive
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Bacterial 70S ribosome inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Burns; Lymphoma, Non-Hodgkin; Candidiasis, Vulvovaginal; Conjunctivitis, Inclusion; Helicobacter Infections; Periodontitis; Vaginosis, Bacterial; Bacterial Infections; Eye Infections; Infections
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: DNA (cytosine-5)-methyltransferase 1 inhibitor
ROUTE OF ADMINISTRATION: INTRAVENOUS
STATUS: Approved
THERAPEUTIC AREA: HEMATOLOGY; OTHER
THERAPEUTIC INDICATION: Burkitt Lymphoma; Glioma; HIV Infections; Head and Neck Neoplasms; Hematologic Neoplasms; Leukemia, Promyelocytic, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Medulloblastoma; Multiple Myeloma; Neuroblastoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Adenocarcinoma, Follicular; Anemia, Aplastic; Anemia, Sickle Cell; Blast Crisis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Neoplasms; Fallopian Tube Neoplasms; Granuloma, Lethal Midline; Hodgkin Disease; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma; Melanoma; Ovarian Neoplasms; Peritoneal Neoplasms; Severe Acute Respiratory Syndrome; Thalassemia; Thyroid Neoplasms; Graft vs Host Disease; Leukemia; Leukemia, Myeloid, Acute; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Myeloproliferative Disorders; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia; Anemia; Anemia, Refractory, with Excess of Blasts; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Bcr/Abl fusion protein
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: CANCER; OTHER
THERAPEUTIC INDICATION: Alzheimer Disease; Brain Neoplasms; Burkitt Lymphoma; Central Nervous System Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Granuloma, Lethal Midline; Head and Neck Neoplasms; Hodgkin Disease; Idiopathic Pulmonary Fibrosis; Immunoblastic Lymphadenopathy; Leukemia, Hairy Cell; Leukemia, Large Granular Lymphocytic; Leukemia, Myeloid; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Mycosis Fungoides; Myelodysplastic Syndromes; Ovarian Neoplasms; Peritoneal Neoplasms; Rhabdomyosarcoma; Scleroderma, Localized; Sezary Syndrome; Waldenstrom Macroglobulinemia; Aging; Brain Diseases; Breast Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cholangiocarcinoma; Colonic Neoplasms; Diffuse Intrinsic Pontine Glioma; Gastrointestinal Stromal Tumors; Glioblastoma; Glioma; Gliosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lung Neoplasms; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Mastocytosis, Systemic; Melanoma; Mesothelioma; Multiple Myeloma; Neuroblastoma; Pancreatic Neoplasms; Pinealoma; Polycythemia Vera; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Renal Insufficiency, Chronic; Severe Acute Respiratory Syndrome; Small Cell Lung Carcinoma; Leukemia; Leukemia, Myeloid, Acute; Prostatic Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Human immunodeficiency virus type 1 protease inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: IMMUNE SYSTEM; OTHER
THERAPEUTIC INDICATION: Autoimmune Diseases; HIV Infections; Infections
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Gliosarcoma; Hemorrhagic Fever, Ebola; Leukemia, Myeloid, Acute; Osteosarcoma; Adenocarcinoma; Adrenal Cortex Neoplasms; Ascites; Brain Neoplasms; Carcinoid Tumor; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Lung Neoplasms; Melanoma; Nasopharyngeal Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroendocrine Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Pheochromocytoma; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Sarcoma, Alveolar Soft Part; Small Cell Lung Carcinoma; Stomach Neoplasms; Thymoma; Thyroid Neoplasms; Urinary Bladder Neoplasms; von Hippel-Lindau Disease; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors; Kidney Neoplasms; Prostatic Neoplasms; Urogenital Neoplasms; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Human immunodeficiency virus type 1 protease inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Amyotrophic Lateral Sclerosis; Hepatitis C; Insulin Resistance; Acquired Immunodeficiency Syndrome; HIV Infections; Infections; Pneumonia, Pneumocystis; Severe Acute Respiratory Syndrome; Virus Diseases